cholesta-5,8-dien-3 beta-ol profile

cholesta-5,8-dien-3 beta-ol: found in tissue of rats given AY 9944 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	129846
CHEBI ID	89982
SCHEMBL ID	2106790
MeSH ID	M0086639

Synonym
cholesta-5,8-dien-3beta-ol
8-dehydrocholesterol
70741-38-7
cholesta-5,8-dien-3 beta-ol
LMST01010242
8-dhc
(3s,10s,13r,14r,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol
unii-r85ba49sys
cholesta-5,8-dien-3-ol, (3beta)-
(3beta)-cholesta-5,8-dien-3-ol
r85ba49sys ,
cholesta-5,8-dien-3-ol,(3b)-
VUKORTMHZDZZFR-BXAZICILSA-N
cholesta-5,8-dien-3b-ol
SCHEMBL2106790
8(9)-dehydrocholesterol
CHEBI:89982
AKOS030255165
3b-cholesta-5,8-dien-3-ol
Q27162187
(3.beta.)-cholesta-5,8-dien-3-ol
cholesta-5,8-dien-3-ol, (3.beta.)-
CS-0059524
HY-113435
F82237
MS-26338
VCA74138
DTXSID801315054
PD086660

Class	Description
steroid	Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Steroid Biosynthesis	21	42
Smith-Lemli-Opitz Syndrome (SLOS)	21	42
CHILD Syndrome	21	42
Desmosterolosis	21	42
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)	21	42
Lysosomal Acid Lipase Deficiency (Wolman Disease)	21	42
Ibandronate Action Pathway	21	43
Simvastatin Action Pathway	21	43
Pravastatin Action Pathway	21	43
Rosuvastatin Action Pathway	21	43
Alendronate Action Pathway	21	43
Hypercholesterolemia	21	42
Lovastatin Action Pathway	21	43
Zoledronate Action Pathway	21	43
Cerivastatin Action Pathway	21	43
Risedronate Action Pathway	21	43
Pamidronate Action Pathway	21	43
Fluvastatin Action Pathway	21	43
Atorvastatin Action Pathway	21	43
Cholesteryl Ester Storage Disease	21	42
Hyper-IgD Syndrome	21	42
Mevalonic Aciduria	21	42
Wolman Disease	21	42
Cholesterol biosynthesis with skeletal dysplasias	0	14

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (2.94)	18.7374
1990's	8 (23.53)	18.2507
2000's	16 (47.06)	29.6817
2010's	9 (26.47)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (2.78%)	5.53%
Reviews	3 (8.33%)	6.00%
Case Studies	10 (27.78%)	4.05%
Observational	0 (0.00%)	0.25%
Other	22 (61.11%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.15	1	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride: An anti-cholesteremic agent that inhibits delta 7-reductase, delta 14 reductase, and sterol biosynthesis.	2.37	2	0
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	2.04	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
silver Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.	6.99	1	0	copper group element atom; elemental silver	Escherichia coli metabolite
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.41	2	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
lathosterol lathosterol: RN given refers to (3beta,5alpha)-isomer. 5alpha-cholest-7-en-3beta-ol : A cholestanoid that is (5alpha)-cholest-7-ene substituted by a beta-hydroxy group at position 3.	2.04	1	0	3beta-sterol; C27-steroid; cholestanoid; Delta(7)-sterol	human metabolite; mouse metabolite
zymostenol zymostenol: RN given refers to (3beta,5alpha)-isomer; RN for cpd without isomeric designation not available 9/88. 5alpha-cholest-8-en-3beta-ol : A cholestanoid that is 5alpha-cholestane substituted by a beta-hydroxy group at position 3.	3.56	2	0	3beta-sterol; cholestanoid	human metabolite; mouse metabolite
27-hydroxycholesterol (25R)-cholest-5-ene-3beta,26-diol : A 26-hydroxycholesterol in which the 25-position has R-configuration.	2.41	2	0	26-hydroxycholesterol	apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent
lanosterol [no description available]	2.04	1	0	14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid	bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
7-dehydrocholesterol [no description available]	7.03	24	1	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; cholestanoid; Delta(5),Delta(7)-sterol	human metabolite; mouse metabolite
desmosterol Desmosterol: An intermediate in the synthesis of cholesterol.. desmosterol : A cholestanoid that is cholesta-5,24-diene substituted by a beta-hydroxy group at position 3. It is an intermediate metabolite obtained during the synthesis of cholesterol.	2	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C27-steroid; cholestanoid	human metabolite; mouse metabolite
gamma-sitosterol clionasterol : A member of the class of phytosterols that is poriferast-5-ene carrying a beta-hydroxy substituent at position 3.	2.04	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; phytosterols	marine metabolite; plant metabolite
cytellin cytellin: a phytosterol preparation of mainly B-sitosterol, that was marketed by Eli Lilly to lower cholesterol 1957 to 1982	2.04	1	0
cholestanol Cholestanol: A cholesterol derivative found in human feces, gallstones, eggs, and other biological matter.	2.04	1	0	cholestanoid
bm 15766 BM 15766: 7-dehydrocholesterol reductase antagonist	3.78	3	0
24-hydroxycholesterol 24-hydroxycholesterol : An oxysterol that is cholesterol which is substituted by a hydroxy group at position 24.	2	1	0	24-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.15	1	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic

Condition	Relationship Strength	Studies	Trials
7-Dehydrocholesterol Reductase Deficiency [description not available]	6.76	22	1
Alobar Holoprosencephaly [description not available]	2.15	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	8.1	5	0
Smith-Lemli-Opitz Syndrome An autosomal recessive disorder of CHOLESTEROL metabolism. It is caused by a deficiency of 7-dehydrocholesterol reductase, the enzyme that converts 7-dehydrocholesterol to cholesterol, leading to an abnormally low plasma cholesterol. This syndrome is characterized by multiple CONGENITAL ABNORMALITIES, growth deficiency, and INTELLECTUAL DISABILITY.	6.76	22	1
Chondrodysplasia Punctata A heterogeneous group of bone dysplasias, the common character of which is stippling of the epiphyses in infancy. The group includes a severe autosomal recessive form (CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC), an autosomal dominant form (Conradi-Hunermann syndrome), and a milder X-linked form. Metabolic defects associated with impaired peroxisomes are present only in the rhizomelic form.	4.53	5	0
Genetic Diseases, X-Chromosome Linked [description not available]	3.4	2	0
Behavior Disorders [description not available]	2.52	2	0
Child Development Deviations [description not available]	2.1	1	0
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	2.52	2	0
Developmental Disabilities Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)	2.1	1	0
Weight Gain Increase in BODY WEIGHT over existing weight.	2.15	1	0
Cerebral Cholesterinosis [description not available]	2.04	1	0
Xanthomatosis, Cerebrotendinous An autosomal recessive lipid storage disorder due to mutation of the gene CYP27A1 encoding a CHOLESTANETRIOL 26-MONOOXYGENASE. It is characterized by large deposits of CHOLESTEROL and CHOLESTANOL in various tissues resulting in xanthomatous swelling of tendons, early CATARACT, and progressive neurological symptoms.	2.04	1	0
Actinic Reticuloid Syndrome [description not available]	2.01	1	0
Symptom Cluster [description not available]	2.01	1	0
Syndrome A characteristic symptom complex.	2.01	1	0
Achalasia [description not available]	2.02	1	0
Esophageal Achalasia A motility disorder of the ESOPHAGUS in which the LOWER ESOPHAGEAL SPHINCTER (near the CARDIA) fails to relax resulting in functional obstruction of the esophagus, and DYSPHAGIA. Achalasia is characterized by a grossly contorted and dilated esophagus (megaesophagus).	2.02	1	0
Hypomelanosis [description not available]	2.04	1	0
Craniofacial Abnormalities Congenital structural deformities, malformations, or other abnormalities of the cranium and facial bones.	2.04	1	0
Alopecia Cicatrisata [description not available]	2.04	1	0
Cataract, Membranous [description not available]	2.04	1	0
Alopecia Absence of hair from areas where it is normally present.	2.04	1	0
Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)	2.04	1	0
Hypopigmentation A condition caused by a deficiency or a loss of melanin pigmentation in the epidermis, also known as hypomelanosis. Hypopigmentation can be localized or generalized, and may result from genetic defects, trauma, inflammation, or infections.	2.04	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.31	2	0
Delayed Effects, Prenatal Exposure [description not available]	1.99	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.01	1	0

cholesta-5,8-dien-3 beta-ol

Description

Cross-References

Synonyms (29)

Drug Classes (1)

Pathways (24)

Research

Studies (34)

Market Indicators

Research Demand Index: 11.84

Study Types

cholesta-5,8-dien-3 beta-ol

Description

Cross-References

Synonyms (29)

Drug Classes (1)

Pathways (24)

Research

Studies (34)

Market Indicators

Research Demand Index: 11.84

Study Types

Related Drugs (17)

Related Conditions (28)